Inhibrx (INBX) IPO Opens, Trades Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Inhibrx Announces Pricing of Initial Public Offering of Common Stock
August 18, 2020 10:00 PM EDTSAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Inhibrx, Inc. ("Inhibrx") (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Inhibrx. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Inhibrx, are expected to be $119.0 million. Inhibrx's common stock is expected to... More
